[ad_1]
(Trends Wide) — An oral pill from Merck and Ridgeback Therapeutics cuts the risk of hospitalization or death from COVID-19 in half, the company reported in a press release on Friday.
Merck said it plans to apply to the US Food and Drug Administration (FDA) for an emergency use authorization “as soon as possible.”
If licensed, molnupiravir could be the first oral antiviral for COVID-19.
News in development.
[ad_2]